KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Account Payables (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Change in Account Payables data on record, last reported at $13.8 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 60.93% year-over-year to $13.8 million; the TTM value through Dec 2025 reached -$15.4 million, down 196.06%, while the annual FY2025 figure was -$15.4 million, 196.06% down from the prior year.
  • Change in Account Payables reached $13.8 million in Q4 2025 per IONS's latest filing, up from -$8.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $35.2 million in Q4 2024 and bottomed at -$20.4 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $192150.0, with a median of -$1.0 million recorded in 2024.
  • Peak YoY movement for Change in Account Payables: crashed 2428.22% in 2021, then skyrocketed 556.04% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $4.7 million in 2021, then plummeted by 195.27% to -$4.5 million in 2022, then surged by 556.04% to $20.6 million in 2023, then surged by 71.06% to $35.2 million in 2024, then tumbled by 60.93% to $13.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $13.8 million in Q4 2025, -$8.8 million in Q3 2025, and -$20.4 million in Q2 2025.